Lanthanum associated abnormal liver function tests in two patients on dialysis: A case report

Journal of Medical Case Reports

Volumn 3, Issue , 2009, Pages

  Namagondlu, Girish ^a   Main, Norman ^a   Yates, Lucy ^a   Mooney, Joanne ^a   Sathyamurthy, Sangita ^a   Daryanani, Indiver ^a   Crowe, Alex ^a   Ledson, Tom ^a,b   Banerjee, Anindya ^a,b  

^a ARROWE PARK HOSPITAL   (United Kingdom)

^b Countess of Chester NHS Foundation Trust ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANTHANUM; SEVELAMER;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SIDE EFFECT; ULTRASOUND;

EID: 75149115224     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-3-9321     Document Type: Article

References (12)

1. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. PC D'Haese GB Spasovski A Sikole A Hutchison TJ Freemont S Sulkova C Swanepoel S Pejanovic L Djukanovic A Balducci G Coen W Sulowicz A Ferreira A Torres S Curic M Popovic N Dimkovic ME De Broe, Kidney Int Suppl 2003 63 73 S78 10.1046/j.1523-1755.63.s85. 18.x
2. Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: comparisons with cadmium in a pulmonary macrophage primary culture system. RJ Palmer JL Butenhoff JB Stevens, Environ Res 1987 43 142 156 10.1016/S0013-9351(87)80066-X 3582304
3. Bioaccumulation of lanthanum and cerium and their effects on the growth of wheat (Triticum aestivum L.) seedlings. X Hu Z Ding Y Chen X Wang L Dai, Chemosphere 2002 48 621 629 10.1016/S0045-6535(02)00109-1 12143937 (Pubitemid 34654392)
4. Hepatobiliary pathology in hemodialysis patients: an autopsy study of 78 cases. MV Pahl ND Vaziri B Dure-Smith R Miller MK Mirahmadi, Am J Gastroenterol 1986 81 9 783 7 3752041
5. Morphological changes of the liver in uremic patients treated with chronic hemodialysis-laparoscopic observations and light-and electron-microscopic studies. S Kawata K Seki Y Minami Y Kameda M Nishikawa S Tarui S Yoshitake M Nishiuchi T Oda, Gastroenterol Jpn 1980 15 3 212 20 7399221
6. Fosrenal (lanthanum carbonate) Prescribing Information. Shire Pharmaceuticals Ltd. Hampshire, UK
7. A long-term (2-year) assessment of the safety and efficacy of lanthanum carbonate, a non-calcium, non-aluminum phosphate binder, for the treatment of hyperphosphatemia. WF Finn MS Joy I Webster, et al. Program and abstracts of the 40th ERA-EDTA World Congress of Nephrology; June 8-12, 2003; Berlin, Germany
8. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. B Lacour A Lucas D Auchere N Ruellan NM de Serre Patey TB Drueke, Kidney Int 2005 67 1062 1069 10.1111/j.1523-1755. 2005.00171.x 15698446
9. Fosrenol (lanthanum carbonate) is well-tolerated in patients requiring hemodialysis: Results of a Phase I clinical trial. M Sack, American Society of Nephrology Annual Meeting 2002; Philadelphia, PA, Nov 1-4, 2002
10. Lanthanum carbonate as a first-line phosphate binder: the "cons". TB Drüeke, Semin Dial 2007 20 4 329 32 10.1111/j.1525-139X.2007.00299.x 17635823
11. Effect of Trivalent Metal Ions on Phase Separation and Membrane Lipid Packing: Role in Lipid Peroxidation. SV Verstraetena LV Nogueirab S Schreierb PI Oteizaa, Archives of Biochemistry and Biophysics 1997 338 121 127 10.1006/abbi.1996.9810 9015396
12. Lanthanide ions inhibit the activity of dihydrofolate reductase from chicken liver. Y Wu, Biometals 2000 13 195 201 10.1023/A:1009220311261 11127890